{"id":64212,"date":"2026-04-29T19:54:12","date_gmt":"2026-04-29T11:54:12","guid":{"rendered":"https:\/\/flcube.com\/?p=64212"},"modified":"2026-04-29T19:54:13","modified_gmt":"2026-04-29T11:54:13","slug":"pfizer-extends-vyndamax-patent-protection-to-2031-through-generic-settlements","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64212","title":{"rendered":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced settlement agreements with generic drug manufacturers <strong>Dexcel Pharma<\/strong>, <strong>Hikma Pharmaceuticals<\/strong>, and <strong>Cipla Ltd.<\/strong>, resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding <strong>VYNDAMAX<\/strong> (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (<strong>ATTR-CM<\/strong>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legal-resolution-summary\">Legal Resolution Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Settlement Date<\/strong><\/td><td>April 28, 2026<\/td><\/tr><tr><td><strong>Litigation Venue<\/strong><\/td><td>U.S. District Court for the District of Delaware<\/td><\/tr><tr><td><strong>Patents<\/strong><\/td><td>VYNDAMAX (tafamidis) composition-of-matter and method-of-use patents<\/td><\/tr><tr><td><strong>Generic Parties<\/strong><\/td><td>Dexcel Pharma, Hikma Pharmaceuticals, Cipla Ltd.<\/td><\/tr><tr><td><strong>Effective Patent Expiry<\/strong><\/td><td>June 1, 2031 (subject to other litigation outcomes)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-market-position\">Product Profile &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Treatment of transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CML)<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> 75% of prescription volume in overall ATTR-CM market<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> Previously anticipated significant decline beginning 2029; now expected stable through mid-2031<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Represents key revenue stream for Pfizer&#8217;s cardiovascular portfolio<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-analysis\">Financial Impact Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Period<\/th><th>Previous Revenue Outlook<\/th><th>Revised Revenue Outlook<\/th><\/tr><\/thead><tbody><tr><td><strong>2028\u20132029<\/strong><\/td><td>Stable<\/td><td>Stable<\/td><\/tr><tr><td><strong>2029\u20132031<\/strong><\/td><td>Significant decline<\/td><td>Relatively stable<\/td><\/tr><tr><td><strong>Post-2031<\/strong><\/td><td>Generic competition expected<\/td><td>Dependent on additional litigation outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The settlements provide Pfizer with approximately two additional years of market exclusivity beyond the originally anticipated 2029 patent expiry, representing substantial incremental revenue opportunity for the blockbuster therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Predictability:<\/strong> Enhanced financial planning horizon through mid-2031<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Maintains dominant market position against potential generic entrants<\/li>\n\n\n\n<li><strong>Pipeline Strategy:<\/strong> Allows continued investment in next-generation ATTR-CM pipeline candidates<\/li>\n\n\n\n<li><strong>Investor Relations:<\/strong> Addresses previous concerns about 2029 cliff risk in analyst communications<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding patent protection, revenue expectations, and litigation outcomes. Actual results may differ due to risks including outcomes of related legal proceedings, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64213,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1834,4720,1941,863,73,309],"class_list":["post-64212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cipla","tag-dexcel-pharma","tag-hikma-pharmaceuticals","tag-nyse-pfe","tag-patents","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64212\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64212\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T11:54:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T11:54:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements\",\"datePublished\":\"2026-04-29T11:54:12+00:00\",\"dateModified\":\"2026-04-29T11:54:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2901.webp\",\"keywords\":[\"Cipla\",\"Dexcel Pharma\",\"Hikma Pharmaceuticals\",\"NYSE: PFE\",\"Patents\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64212#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64212\",\"name\":\"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2901.webp\",\"datePublished\":\"2026-04-29T11:54:12+00:00\",\"dateModified\":\"2026-04-29T11:54:13+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64212\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64212#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64212","og_locale":"en_US","og_type":"article","og_title":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements","og_description":"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).","og_url":"https:\/\/flcube.com\/?p=64212","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-29T11:54:12+00:00","article_modified_time":"2026-04-29T11:54:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64212#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64212"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements","datePublished":"2026-04-29T11:54:12+00:00","dateModified":"2026-04-29T11:54:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64212"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64212#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","keywords":["Cipla","Dexcel Pharma","Hikma Pharmaceuticals","NYSE: PFE","Patents","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64212#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64212","url":"https:\/\/flcube.com\/?p=64212","name":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64212#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64212#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","datePublished":"2026-04-29T11:54:12+00:00","dateModified":"2026-04-29T11:54:13+00:00","description":"Pfizer Inc. (NYSE: PFE) announced settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd., resolving patent infringement lawsuits filed in the U.S. District Court for the District of Delaware regarding VYNDAMAX (tafamidis), a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64212#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64212"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64212#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","width":1080,"height":608,"caption":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64212#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Extends VYNDAMAX Patent Protection to 2031 Through Generic Settlements"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64212"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64212\/revisions"}],"predecessor-version":[{"id":64214,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64212\/revisions\/64214"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64213"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}